1st ENDOTARGET Webinar
On October 24, 2024, the ENDOTARGET consortium hosted an insightful webinar titled “Fecal Microbiota Transplantation as a Treatment for Microbiota Dysbiosis-Associated Conditions”. Held from 3-5 pm CEST, the event brought together experts and researchers to discuss the potential of fecal microbiota transplantation (FMT) as a therapeutic intervention for conditions linked to microbial imbalances. With presentations from distinguished researchers and interactive Q&A sessions, the webinar offered valuable perspectives on the evolving applications of FMT.
A Comprehensive Overview of FMT and Its Indications
The session began with a presentation by Dr. Josbert Keller from HMC Hospital and Leiden University Medical Centre in the Netherlands. Titled “Overview of FMT and Its Indications”, Dr. Keller’s talk provided a foundational understanding of FMT, explaining its mechanisms and clinical application. He highlighted how FMT has gained traction as a treatment for Clostridium difficile infection and explored its potential applications for other conditions.
Investigating Microbiome Changes in FMT
Following Dr. Keller, young researcher Dr. Anna Hartikainen from the University of Helsinki presented “Microbiome Changes in FMT”, a closer look at the microbiome alterations that occur post-transplantation. She shared data from recent studies that revealed shifts in microbial diversity and function after FMT, suggesting that FMT is effective to modify recipients’ microbiota composition.
A Pilot FMT Trial for Ankylosing Spondylitis: The ENDOTARGET Perspective
The webinar concluded with a presentation by Dr. Reetta Satokari, a project partner of ENDOTARGET from the University of Helsinki. Her talk, titled “Pilot-Scale FMT Trial on Ankylosing Spondylitis”, introduced an ongoing FMT trial focused on ankylosing spondylitis, a clinical trial within ENDOTARGET. Dr. Satokari explained the rationale behind using FMT to address gut-joint axis issues in ankylosing spondylitis patients and shared detail of the ongoing trial.
With this webinar, the ENDOTARGET project provided a dynamic platform for discussing cutting-edge research and clinical insights on FMT as a treatment option for microbiota dysbiosis-associated conditions. Stay tuned for more!
Have you missed the webinar?
No worries!
You can watch the recordings here
